Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcturus Therapeutics Ltd (ARCT)

Arcturus Therapeutics Ltd (ARCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

1 Under-$10 Stock Set to Surge as Much as 963% in 2026

Stocks trading under $10 rarely come with the potential for life-changing gains, especially in today’s cautious market. In most sectors, that kind of upside is almost unheard of. Some biotech stocks, however, are an exception. When encouraging clinical data and regulatory milestones align, a single breakthrough can rapidly reprice a biotech stock. That is precisely why Wall Street expects this under-$10 biotech company to skyrocket by as much as 404% in 2026. Let’s find out why. 

Arcturus Therapeutics (ARCT) is a biotechnology company that develops messenger RNA (mRNA)-based medicines and vaccines. Instead of treating symptoms, Arcturus seeks to address the root...

Fundamentals

See More
  • Market Capitalization, $K 192,647
  • Shares Outstanding, K 28,414
  • Annual Sales, $ 152,310 K
  • Annual Income, $ -80,940 K
  • EBIT $ -78 M
  • EBITDA $ -75 M
  • 60-Month Beta 2.24
  • Price/Sales 2.16
  • Price/Cash Flow N/A
  • Price/Book 0.82

Options Overview Details

View History
  • Implied Volatility 97.25% (-150.30%)
  • Historical Volatility 57.05%
  • IV Percentile 55%
  • IV Rank 12.87%
  • IV High 339.05% on 01/02/26
  • IV Low 61.54% on 01/24/25
  • Expected Move (DTE 4) 0.77 (11.41%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 205
  • Volume Avg (30-Day) 336
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 10,179
  • Open Int (30-Day) 12,104
  • Expected Range 6.01 to 7.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.87
  • Number of Estimates 4
  • High Estimate -0.53
  • Low Estimate -1.18
  • Prior Year -1.11
  • Growth Rate Est. (year over year) +21.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.01 +21.20%
on 12/31/25
7.53 -3.25%
on 12/15/25
-0.17 (-2.28%)
since 12/12/25
3-Month
5.85 +24.62%
on 11/20/25
24.17 -69.84%
on 10/21/25
-11.66 (-61.53%)
since 10/10/25
52-Week
5.85 +24.62%
on 11/20/25
24.17 -69.84%
on 10/21/25
-10.69 (-59.45%)
since 01/10/25

Most Recent Stories

More News
1 Under-$10 Stock Set to Surge as Much as 963% in 2026

The high price estimate for Arcturus suggests the stock can rally as high as 963%. Is it a far-fetched target?

$SPX : 6,966.28 (+0.65%)
ARCT : 7.30 (+7.67%)
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics...

ARCT : 7.30 (+7.67%)
Arcturus Therapeutics to Attend Upcoming Investor Conference

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics...

ARCT : 7.30 (+7.67%)
Arcturus Therapeutics: Q3 Earnings Snapshot

Arcturus Therapeutics: Q3 Earnings Snapshot

ARCT : 7.30 (+7.67%)
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

Encouraging CF interim Phase 2 data support continued and expanded trial design 12-week safety and preliminary efficacy study in up to 20 CF participants planned to start...

ARCT : 7.30 (+7.67%)
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP  is investigating potential violations of the federal securities laws involving Arcturus Therapeutics Holdings Inc. ("Arcturus")...

ARCT : 7.30 (+7.67%)
Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics...

ARCT : 7.30 (+7.67%)
2 Stocks to Buy Under $10 That Wall Street Loves

While penny stocks are risky, they also have the potential to deliver outsized gains.

LTRN : 3.57 (+2.29%)
HOTH : 1.0700 (-0.93%)
ARCT : 7.30 (+7.67%)
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics...

ARCT : 7.30 (+7.67%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Arcturus Therapeutics Holdings Inc.  ("Arcturus" or the "Company") (NASDAQ: ARCT). Such...

ARCT : 7.30 (+7.67%)

Business Summary

Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as...

See More

Key Turning Points

3rd Resistance Point 7.20
2nd Resistance Point 7.09
1st Resistance Point 6.93
Last Price 7.30
1st Support Level 6.66
2nd Support Level 6.55
3rd Support Level 6.39

See More

52-Week High 24.17
Fibonacci 61.8% 17.17
Fibonacci 50% 15.01
Fibonacci 38.2% 12.85
Last Price 7.30
52-Week Low 5.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar